Could a Parkinson's drug fix antipsychotic side effects?

NCT ID NCT03575000

Not yet recruiting Disease control Sponsor: VA Pittsburgh Healthcare System Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This small pilot study tests whether bromocriptine, a drug used for Parkinson's, can safely improve blood sugar problems in people with schizophrenia who have prediabetes from antipsychotic medications. Fifteen adults will take bromocriptine for 6 weeks, with researchers monitoring safety, blood sugar, and psychiatric symptoms. The goal is to see if it's worth studying further as a way to prevent type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bromocriptine (a dopamine agonist pill)
What this could lead to: If it works, this could point toward a safe, cheap way to prevent or delay type 2 diabetes in people with schizophrenia who take antipsychotics.
What could go wrong: This is a very small, early pilot study with only 15 people and no placebo group. It focuses on safety, not proof of effectiveness, so results may not lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREDIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prediabetes syndrome schizophrenia type 2 diabetes mellitus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREDIABETES SCHIZOPHRENIA

Contacts and locations

Locations

VA Pittsburgh Healthcare System

Pittsburgh, Pennsylvania, 15240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.